Avalo Therapeutics Reports $36.4 Million Net Loss in Q2 2026, Driven by Increased R&D Expenses

Avalo Therapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the second quarter of 2026, revealing a net loss of $36.4 million for the quarter, compared to a loss of $20.8 million in the same period last year. For the six months ending June 30, 2026, the company recorded a net loss of $56.0 million, up from $33.9 million in the prior year. The increase in losses is attributed to heightened research and development expenses, which rose to $23.4 million in Q2 2026 from $14.1 million in Q2 2025, largely due to a $10 million milestone payment related to the company's lead drug candidate, abdakibart, as it progresses into a Phase 3 trial.

Avalo's total assets surged to $490.8 million as of June 30, 2026, a substantial increase from $116.5 million at the end of 2025. This growth was primarily driven by a successful equity offering that generated net proceeds of approximately $405 million in May 2026. The company’s cash and cash equivalents stood at $85.4 million, alongside short-term investments of $314.9 million, reflecting a strong liquidity position to support ongoing operations and development activities.

In terms of operational metrics, Avalo's research and development expenses for the first half of 2026 totaled $37.5 million, compared to $23.2 million in the same period of 2025. The increase was influenced by the company's strategic focus on advancing its pipeline, particularly the development of abdakibart for hidradenitis suppurativa, which has shown promising results in Phase 2 trials. The company also reported a rise in general and administrative expenses, which reached $15.0 million for the first half of 2026, up from $10.8 million in the previous year, driven by increased stock-based compensation and higher operational costs.

Avalo's strategic initiatives included the completion of the AlmataBio Buyout Agreement, which allowed the company to settle a $15 million milestone obligation for abdakibart with a combination of cash and stock. This agreement eliminated future contingent liabilities related to the AlmataBio acquisition. Looking ahead, Avalo anticipates continued investment in its clinical programs, particularly as it prepares for pivotal trials and explores additional indications for its therapies. The company expects its existing cash reserves to be sufficient to fund operations into 2029, although it may seek additional financing through equity sales or strategic partnerships to support its growth objectives.